Cartesian Therapeutics, Inc. (RNAC) has disclosed a new risk, in the Manufacturing category.
Cartesian Therapeutics, Inc. faces substantial risks as it expands its manufacturing capabilities for therapies such as Descartes-08. The complexity of biological manufacturing and patient-specific production presents potential for delays and errors that could hinder clinical trials and inflate costs. Dependency on third-party laboratories and competition for manufacturing resources adds to the precariousness of Cartesian’s operations. Moreover, meeting the stringent regulatory requirements consistently throughout scaling efforts is critical to maintain progress towards commercialization and to avoid costly setbacks or disruptions in supply chains.
The average RNAC stock price target is $2.00, implying 210.70% upside potential.
To learn more about Cartesian Therapeutics, Inc.’s risk factors, click here.
